(Q44837280)

6 December 2017

Preemptive use of lamivudine in breast cancer patients carrying hepatitis B virus undergoing cytotoxic chemotherapy: a longitudinal study (English)

1 reference

6 December 2017

0 references

1 reference

1 reference

1 reference

Meng-Shen Dai

1

1 reference

6 December 2017

Pei-Fen Wu

2

1 reference

6 December 2017

Jang-Jih Lu

3

1 reference

6 December 2017

Rong-Yaun Shyu

4

1 reference

6 December 2017

Tsu-Yi Chao

5

1 reference

6 December 2017

1 March 2004

1 reference

Supportive Care in Cancer

6 December 2017

1 reference

6 December 2017

12

1 reference

6 December 2017

3

1 reference

6 December 2017

191-196

1 reference

https://scigraph.springernature.com/pub.10.1007/s00520-003-0549-2

6 December 2017

0 references

cites work

Lamivudine therapy for chronic hepatitis B: a six-month randomized dose-ranging study

1 reference

12 December 2020

Reactivation of precore mutant hepatitis B virus leading to fulminant hepatic failure following cytotoxic treatment

1 reference

12 December 2020

Prevention of hepatitis B flare-up during chemotherapy using lamivudine: case report and review of the literature

1 reference

12 December 2020

Hepatitis B reactivation after lamivudine

1 reference

12 December 2020

Sequential analyses of the mutations in the core upstream and precore regions of hepatitis B virus genome in anti-HBe positive-carriers developing acute exacerbation

1 reference

12 December 2020

Hepatitis B virus reactivation in patients undergoing cytotoxic chemotherapy for solid tumours: precore/core mutations may play an important role

1 reference

12 December 2020

Identification and characterization of mutations in hepatitis B virus resistant to lamivudine. Lamivudine Clinical Investigation Group

1 reference

12 December 2020

Reactivation of precore mutant hepatitis B virus in chemotherapy-treated patients

1 reference

12 December 2020

Lamivudine in the treatment of hepatitis B virus reactivation during cytotoxic chemotherapy

1 reference

12 December 2020

Fatal reactivation of chronic hepatitis B virus infection following withdrawal of chemotherapy in lymphoma patients

1 reference

12 December 2020

Long-term follow-up of patients with anti-HBe/HBV DNA-positive chronic hepatitis B treated for 12 months with lamivudine

1 reference

12 December 2020

Hepatitis B infection in patients with lymphomas

1 reference

12 December 2020

Primary prophylaxis with lamivudine of hepatitis B virus reactivation in chronic HbsAg carriers with lymphoid malignancies treated with chemotherapy.

1 reference

12 December 2020

Lamivudine as initial treatment for chronic hepatitis B in the United States

1 reference

12 December 2020

Lamivudine allows completion of chemotherapy in lymphoma patients with hepatitis B reactivation

1 reference

12 December 2020

Long-term therapy of chronic hepatitis B with lamivudine.

1 reference

12 December 2020

Mutation in HBV RNA-dependent DNA polymerase confers resistance to lamivudine in vivo

1 reference

12 December 2020

Hepatitis B genotypes correlate with clinical outcomes in patients with chronic hepatitis B

1 reference

12 December 2020

Hepatitis B virus reactivation in breast cancer patients receiving cytotoxic chemotherapy: a prospective study

1 reference

12 December 2020

Response of pre-core mutant chronic hepatitis B infection to lamivudine

1 reference

12 December 2020

Lamivudine for the treatment of hepatitis B virus reactivation following chemotherapy for non-Hodgkin's lymphoma

1 reference

12 December 2020

High hepatitis B virus (HBV) DNA viral load as the most important risk factor for HBV reactivation in patients positive for HBV surface antigen undergoing autologous hematopoietic cell transplantation

1 reference

12 December 2020

Chemotherapy and bone marrow transplantation for cancer patients who are also chronic hepatitis B carriers: a review of the problem

1 reference

12 December 2020

Successful treatment with lamivudine for fulminant reactivated hepatitis B infection following intensive therapy for high-grade non-Hodgkin's lymphoma

1 reference

12 December 2020

A placebo-controlled phase I/II study of adefovir dipivoxil in patients with chronic hepatitis B virus infection

1 reference

12 December 2020

Prevalence of hepatitis B virus marker positivity and evolution of hepatitis B virus profile, during chemotherapy, in patients with solid tumours

1 reference

12 December 2020

Efficacy of lamivudine in HBeAg-negative chronic hepatitis B.

1 reference

12 December 2020

Incidence of hepatitis B virus infections in preschool children in Taiwan.

1 reference

12 December 2020

Steroid-free chemotherapy decreases the risk of hepatitis flare-up in hepatitis B virus carriers with non-Hodgkin's lymphoma

1 reference

12 December 2020

Reactivation of hepatitis B but not hepatitis C in patients with malignant lymphoma and immunosuppressive therapy. A prospective study in 305 patients.

1 reference

12 December 2020

Sequence variations of precore/core and precore promoter regions of hepatitis B virus in patients with or without viral reactivation during cytotoxic chemotherapy.

1 reference

12 December 2020

Hepatitis B virus reactivation during cytotoxic chemotherapy-enhanced viral replication precedes overt hepatitis

1 reference

12 December 2020

Acute exacerbation of hepatitis due to reactivation of hepatitis B virus with mutations in the core region after chemotherapy for malignant lymphoma

1 reference

12 December 2020

10.1007/S00520-003-0549-2

Identifiers

DOI

1 reference

6 December 2017

1 reference